Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

pembrolizumab 42Carboplatin 38Cisplatin 34Paclitaxel 27Pemetrexed 23Gemcitabine 23Nivolumab 22Dexamethasone 17Ipilimumab 16Rituximab 15Fluorouracil 14Capecitabine 14Docetaxel 13trastuzumab deruxtecan 12durvalumab 12atezolizumab 12Cyclophosphamide 12Trastuzumab 11Lenalidomide 11olaparib 10130-nm albumin-bound paclitaxel 10Prednisone 9venetoclax 8daratumumab 8Oxaliplatin 8Cytarabine 8Bortezomib 8Bevacizumab 8zanubrutinib 7Vinorelbine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × S 1 (combination) × Clear all
NCT03615326 2025-12-11

MK-3475-811

Merck Sharp & Dohme LLC

Phase 3 Completed
738 enrolled 22 charts 3 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡